Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2013 and its Form 10-Q for the quarter ended March 31, 2014.  The reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Contacts Sanofi:Media Relations

Investor Relations Jack Cox

Sebastien MartelTel: +33 (0) 1 53 77 94 74

Tel: +33 (0)1 53 77 45 45Mobile: +33 (0) 6 78 52 05 36

E-mail: IR@sanofi.com E-mail: Jack.Cox@sanofi.com <
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Global Stem Cells Group ... the company’s first cellular and regenerative medicine symposium in ... day, hands-on stem cell training class Oct. 10. The ... M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... in regenerative medicine and recent advances in cellular therapies, ...
(Date:5/26/2015)... Texas , May 26, 2015  A simple ... Health Science Center to detect early Alzheimer,s disease is ... adults. Detailed standardized guidelines that are needed ... have been published in Alzheimer,s & Dementia . ... of an international working group that includes UNT Health ...
(Date:5/26/2015)... ANGELES , 26. mája 2015 ... v mene svojej rodiny prezidentom Barackovi Obamovi a ... v súvislosti so stratou Dr. Rongxiang Xu ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol ... dobe a jeho odhodlanie v oblasti vedy a ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... N.J. , Feb. 5 Amicus Therapeutics (Nasdaq: ... John F. Crowley as Chairman of the Board in ... immediately.  Mr. Crowley will succeed Donald J. Hayden, Jr. , ... "The Board,s decision to elect Mr. Crowley as Chairman of the ...
... chronic wounds can be deadly to maggot ,biosurgeons, used ... journal Microbiology . The findings could lead to ... novel antibiotics. Scientists from the Copenhagen Wound Healing ... in Denmark showed that maggots applied to simulated wounds ...
... made of clay and a bit of high-grade plastic draws oil ... lab tests show that oil absorbed can be squeezed back out ... the material, called an aerogel, believe it will effectively clean up ... and roadways, rivers and oceans. , The EPA estimates that 10 ...
Cached Biology Technology:Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2Bacteria toxic to wound-treating maggots 2New material absorbs, conserves oil 2
(Date:5/26/2015)... , May 26, 2015 ... the addition of the "Saudi Arabia Biometric ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... is projected to grow at over ... growth is attributed to the surging demand for ...
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... abilities to counsel patients on a healthy diet and exercise ... a study by the University of Michigan Cardiovascular Center. ... being overweight, and if the doctor had adequate training in ... published online ahead of print Oct. 1 in Preventive ...
... CITYResearchers at Huntsman Cancer Institute (HCI) at the University of ... the maintenance and repair of the cell,s cytoskeleton, or internal ... cell. The research has implications for cancer, as well as ... with disease. The research was published in the Sep. 14, ...
... N.Y. -- A $634,000 grant from the Department of ... to investigate a trio of environmental factors and their ... two-year project, headed by Murali Ramanathan, PhD, tests the ... metabolism and increased levels of anti-Epstein-Barr virus (EBV) each ...
Cached Biology News:Doctor's health habits affect patient counseling 2Study offers first explanation of how cells rapidly repair and maintain structure 2Gene-environmental interactions and MS progression is focus of new study 2
Request Info...
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: